Anti-inflammatory effect of quercetin in a whole orbital tissue culture of graves' orbitopathy

British Journal of Ophthalmology

Volumn 96, Issue 8, 2012, Pages 1117-1121

  Yoon, Jin Sook ^a   Chae, Min Kyung ^a   Lee, Sang Yeul ^a   Lee, Eun Jig ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Brain Korea 21 Project for Medical Science   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; MESSENGER RNA; QUERCETIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENDOCRINE OPHTHALMOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; GENE; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN TISSUE; INTERLEUKIN 1BETA GENE; INTERLEUKIN 6 GENE; INTERLEUKIN 8 GENE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FOLDING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TISSUE CULTURE; TUMOR NECROSIS FACTOR ALPHA GENE; VISUAL THRESHOLD;

ADIPOSE TISSUE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CONNECTIVE TISSUE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAVES OPHTHALMOPATHY; HUMANS; L-LACTATE DEHYDROGENASE; ORBITAL DISEASES; ORGAN CULTURE TECHNIQUES; QUERCETIN; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84864833156     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-301537     Document Type: Article

References (32)

1. Garrity JA, Bahn RS. Pathogenesis of Graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 2006;142:147-53.
2. Kuriyan AE, Phipps RP, Feldon SE. The eye and thyroid disease. Curr Opin Ophthalmol 2008;19:499-506.
3. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010;362:726-38.
4. Lehmann GM, Feldon SE, Smith TJ, et al. Immune mechanisms in thyroid eye disease. Thyroid 2008;18:959-65.
5. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000;21:168-99. (Pubitemid 32275594)
6. Yoon JS, Lee HJ, Choi SH, et al. Quercetin inhibits IL-1beta-induced inflammation, hyaluronan production and adipogenesis in orbital fibroblasts from Graves' orbitopathy. PLoS One 2011;6:e26261.
7. Comalada M, Camuesco D, Sierra S, et al. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol 2005;35:584-92. (Pubitemid 40331335)
8. Ying B, Yang T, Song X, et al. Quercetin inhibits IL-1 beta-induced ICAM-1 expression in pulmonary epithelial cell line A549 through the MAPK pathways. Mol Biol Rep 2009;36:1825-32.
9. Vasquez-Garzon VR, Arellanes-Robledo J, Garcia-Roman R, et al. Inhibition of reactive oxygen species and pre-neoplastic lesions by quercetin through an antioxidant defense mechanism. Free Radic Res 2009;43:128-37.
10. Rotelli AE, Aguilar CF, Pelzer LE. Structural basis of the anti-inflammatory activity of quercetin: inhibition of the 5-hydroxytryptamine type 2 receptor. Eur Biophys J 2009;38:865-71.
11. Rogerio AP, Dora CL, Andrade EL, et al. Anti-inflammatory effect of quercetin-loaded microemulsion in the airways allergic inflammatory model in mice. Pharmacol Res 2010;61:288-97.
12. van Steensel L, van Hagen PM, Paridaens D, et al. Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves' ophthalmopathy. Br J Ophthalmol 2011;95:735-8.
13. Baker G, Mazziotti G, von Ruhland C, et al. Reevaluating thyrotropin receptor-induced mouse models of Graves' disease and ophthalmopathy. Endocrinology 2005;146:835-44. (Pubitemid 40129841)
14. Mourits MP, Prummel MF, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997;47:9-14. (Pubitemid 27313981)
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-8. (Pubitemid 34164012)
16. Kumar S, Bahn RS. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 2003;88:4246-50. (Pubitemid 37153727)
17. Smith TJ. Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid 2002;12:197-203. (Pubitemid 34259799)
18. Pritchard J, Horst N, Cruikshank W, et al. Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 2002;168:942-50. (Pubitemid 34049599)
19. Heufelder AE, Bahn RS. Graves' immunoglobulins and cytokines stimulate the expression of intercellular adhesion molecule-1 (ICAM-1) in cultured Graves' orbital fibroblasts. Eur J Clin Invest 1992;22:529-37.
20. Hiromatsu Y, Yang D, Bednarczuk T, et al. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2000;85:1194-9. (Pubitemid 32269371)
21. Hwang CJ, Afifiyan N, Sand D, et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci 2009;50:2262-8.
22. Chen B, Tsui S, Smith TJ. IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol 2005;175:1310-19. (Pubitemid 41095021)
23. Burnstine MA, Elner SG, Elner VM. Orbital fibroblast chemokine modulation: effects of dexamethasone and cyclosporin A. Br J Ophthalmol 1998;82:318-22. (Pubitemid 28177125)
24. Raychaudhuri N, Douglas RS, Smith TJ. PGE2 induces IL-6 in orbital fibroblasts through EP2 receptors and increased gene promoter activity: implications to thyroid-associated ophthalmopathy. PLoS One 2010;5:e15296.
25. Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophysica Acta 2011;1813:878-88.
26. Kopf M, Bachmann MF, Marsland BJ. Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 2010;9:703-18.
27. Wakelkamp IM, Bakker O, Baldeschi L, et al. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf) 2003;58:280-7. (Pubitemid 36308115)
28. Bischoff SC. Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care 2008;11:733-40.
29. Manach C, Morand C, Crespy V, et al. Quercetin is recovered in human plasma as conjugated derivatives which retain antioxidant properties. FEBS Lett 1998;426:331-6. (Pubitemid 28218374)
30. Moon JH, Tsushida T, Nakahara K, et al. Identification of quercetin 3-O-beta-D-glucuronide as an antioxidative metabolite in rat plasma after oral administration of quercetin. Free Radic Biol Med 2001;30:1274-85. (Pubitemid 32463938)
31. Ishizawa K, Yoshizumi M, Kawai Y, et al. Pharmacology in health food: metabolism of quercetin in vivo and its protective effect against arteriosclerosis. J Pharmacol Sci 2011;115:466-70.
32. Harwood M, Danielewska-Nikiel B, Borzelleca JF, et al. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007;45:2179-205. (Pubitemid 47451573)